Inhibition of HGF/MET Signaling Decreases Overall Tumor Burden and Blocks Malignant Conversion in Tpl2-Related Skin Cancer

Oncogenesis - United States
doi 10.1038/s41389-018-0109-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

HGF/Met Signaling in Cancer Invasion: The Impact on Cytoskeleton Remodeling

Cancers
Cancer ResearchOncology
2017English

Mechanisms of HGF/Met Signaling to BRK and Sam68 in Breast Cancer Progression

Hormones and Cancer
OncologyCancer ResearchEndocrinologyAutonomic SystemsEndocrineMetabolismDiabetes
2011English

Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage Over Inhibiting HGF/MET Signaling

Cancer Research
Cancer ResearchOncology
2015English

Inhibition of NF-kappa B Activity in Mammary Epithelium Increases Tumor Latency and Decreases Tumor Burden

Oncogene
Cancer ResearchGeneticsMolecular Biology
2010English

The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

MAP Kinase Kinase Kinase 8 (MAP3K8; COT; TPL2); C-Met Proto-Oncogene (MET; HGFR); Hepatocyte Growth Factor/Scatter Factor (HGF/SF)

Science-Business eXchange
2012English

Resection of the Primary Tumor Improves Survival in Metastatic Breast Cancer by Reducing Overall Tumor Burden

Surgery
Surgery
2013English

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2014English

HGF/c-Met Axis Drives Cancer Aggressiveness in the Neoadjuvant Setting of Ovarian Cancer

Gynecologic Oncology
GynecologyOncologyObstetrics
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy